IP Verse

Amgen Research (munich) Gmbh opposition analysis

COMPANY ANALYSIS

Latest patents of Amgen Research (munich) Gmbh opposed by its competitors

Patent:
EP2637670
Grant Date:
Mar 13, 2024
Title:
Prevention Of Adverse Effects Caused By Cd3 Specific Binding Domains
Oppositions:
2
Patent:
EP4058148
Grant Date:
Mar 13, 2024
Title:
Dosing Regimen For Anti-Bcma Agents
Oppositions:
2
Patent:
EP3531133
Grant Date:
Aug 23, 2023
Title:
Risk-Stratification Of B-Precursor Acute Lymphoblastic Leukemia Patients
Oppositions:
1
Patent:
EP3411402
Grant Date:
Dec 22, 2021
Title:
Bcma And Cd3 Bispecific T Cell Engaging Antibody Constructs
Oppositions:
1
Patent:
EP3228315
Grant Date:
Nov 25, 2020
Title:
Prevention Of Adverse Effects Caused By Cd3 Specific Binding Domains
Oppositions:
2
Patent:
EP3412687
Grant Date:
Mar 18, 2020
Title:
Methods For Treating Dlbcl
Oppositions:
1
Patent:
EP2780375
Grant Date:
Sep 11, 2019
Title:
Binding Molecules For Bcma And Cd3
Oppositions:
8
Patent:
EP2780374
Grant Date:
Aug 21, 2019
Title:
Binding Molecules For Bcma And Cd3
Oppositions:
7
Patent:
EP3149480
Grant Date:
Dec 26, 2018
Title:
Risk-Stratification Of B-Precursor Acute Lymphoblastic Leukemia Patients
Oppositions:
1
Patent:
EP3018145
Grant Date:
Apr 4, 2018
Title:
Means And Methods For Treating Dlbcl
Oppositions:
1

Competitors of Amgen Research (munich) Gmbh

JAMES POOLE LIMITED

REGENERON PHARMACEUTICALS, INC.

SANOFI

Want to track Amgen Research (munich) Gmbh?

Feel free to send us a message here and we will get back to you